Stereotactic body radiotherapy: A critical review for nonradiation oncologists

Cancer

Volumn 120, Issue 7, 2014, Pages 942-954

  Kirkpatrick, John P ^a   Kelsey, Christopher R ^a   Palta, Manisha ^a   Cabrera, Alvin R ^a   Salama, Joseph K ^a   Patel, Pretesh ^a   Perez, Bradford A ^a   Lee, Jason ^a   Yin, Fang Fang ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

Author keywords

intensity modulated radiotherapy; liver cancer; lung cancer; normal tissue complications; oligometastases; radiosurgery; spine metastases; stereotactic body radiotherapy

Indexed keywords

COMPUTER ASSISTED RADIOTHERAPY; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; METASTASIS POTENTIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DEPTH DOSE; RADIATION DOSE; RADIOTHERAPY PLANNING SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE METASTASIS; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT INDICATION;

INTENSITY-MODULATED RADIOTHERAPY; LIVER CANCER; LUNG CANCER; NORMAL TISSUE COMPLICATIONS; OLIGOMETASTASES; RADIOSURGERY; SPINE METASTASES; STEREOTACTIC BODY RADIOTHERAPY;

HUMANS; NEOPLASMS; RADIOSURGERY;

EID: 84899434960     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28515     Document Type: Review

References (138)

1. Despeignes V,. Observation concernant un cas de cancer de l'estomac traite par les rayons Roentgen. Lyon Med. 1896; 82: 428-430;503.
2. Freund L,. Ein mit roentgen-strahlen behandelter fall von naevus pigmentosus piliferus. Wiener Med Woch. 1897; 47: 428-434.
3. Kogelnik HD,. Inauguration of radiotherapy as a new scientific speciality by Leopold Freund 100 years ago. Radiother Oncol. 1997; 42: 203-211.
4. Halperin EC, Wazer DE, Perez CA,. The discipline of radiation oncology. In:, Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez & Brady's Principles and Practice of Radiation Oncology. 6th edition. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2013: 2-60.
5. Coutard H,. Principles of X-ray therapy of malignant disease. Lancet. 1934; 2: 1-8.
6. Fowler JF., Fractionation and therapeutic gain. In:, Steele GE, Adams GE, Peckham MT, editors. Biological Basis of Radiotherapy. Amsterdam, Netherlands: Elsevier Science, 1983: 181-194.
7. American Society for Radiation Oncology (ASTRO). Radiation Therapy for Cancer (patient education booklet), 4th edition. Fairfax, VA: ASTRO; 2011.
8. Kirkpatrick JP, Yin FF, Sampson JH,. Radiotherapy and radiosurgery for tumors of the central nervous system. Surg Oncol Clin North Am. 2013; 22: 445-461.
9. Kirkpatrick JP, Brenner DJ, Orton CG,. Point/Counterpoint. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Med Phys. 2009; 36: 3381-3384.
10. Park C, Papiez L, Zhang S, Story M, Timmerman RD,. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 847-852.
11. Fuks Z, Kolesnick R,. Engaging the vascular component of the tumor response. Cancer Cell. 2005; 8: 89-91.
12. Kavanagh BD, Timmerman RD,. Stereotactic radiosurgery and stereotactic body radiation therapy: an overview of technical considerations and clinical applications. Hematol Oncol Clin North Am. 2006; 20: 87-95.
13. Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M,. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol. 2011; 187: 284-291.
14. Solberg TD, Balter JM, Benedict SH, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary. Pract Radiat Oncol. 2012; 2: 2-9.
15. Klein EE, Hanley J, Bayouth J, et al. Task Group 142 report: quality assurance of medical accelerators. Med Phys. 2009; 36: 4197-4212.
16. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37: 4078-4101.
17. Bissonnette JP, Balter PA, Dong L, et al. Quality assurance for image-guided radiation therapy utilizing CT-based technologies: a report of the AAPM TG-179. Med Phys. 2012; 39: 1946-1963.
18. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27: 3290-3296.
19. Bral S, Gevaert T, Linthout N, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Results of a phase II trial. Int J Radiat Oncol Biol Phys. 2011; 80: 1343-1349.
20. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75: 677-682.
21. Hoyer M, Roed H, Hansen AT, et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 66: S128-S135.
22. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63: 1427-1431.
23. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer. 2010; 68: 72-77.
24. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070-1076.
25. Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 73: 1235-1242.
26. Olsen JR, Robinson CG, El Naqa, I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e299-e303.
27. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007; 2: S94-S100.
28. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR) - can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012; 102: 335-342.
29. Linda A, Trovo M, Bradley JD,. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011; 79: 147-154.
30. Essler M, Wantke J, Mayer B, et al. Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol. 2013; 189: 495-501.
31. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24: 4833-4839.
32. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving > 30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76: 796-801.
33. Pettersson N, Nyman J, Johansson KA,. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol. 2009; 91: 360-368.
34. Voroney JP, Hope A, Dahele MR, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol. 2009; 4: 1035-1037.
35. Welsh J, Thomas J, Shah D, et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 81: 91-96.
36. Hoppe BS, Laser B, Kowalski AV, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys. 2008; 72: 1283-1286.
37. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol. 2009; 93: 408-413.
38. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M,. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993; 27: 117-123.
39. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK,. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002; 53: 810-821.
40. Blomgren H, Lax I, Näslund I, Svanström R,. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995; 34: 861-870.
41. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81: e447-e453.
42. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013; 31: 1631-1639.
43. Cárdenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12: 218-225.
44. Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008; 8: 351.
45. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010; 10: 475.
46. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010; 9: 479-487.
47. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol. 2006; 45: 831-837.
48. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012; 118: 3191-3198.
49. Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol. 2010; 102: 209-214.
50. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008; 26: 657-664.
51. Ambrosino G, Polistina F, Costantin G, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009; 29: 3381-3384.
52. Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010; 78: 486-493.
53. Herfarth KK, Debus J, Wannenmacher M,. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004; 38: 100-105.
54. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006; 45: 823-830.
55. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P,. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007; 67: 793-798.
56. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009; 27: 1585-1591.
57. Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011; 18: 1081-1087.
58. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27: 1572-1578.
59. van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010; 97: 377-382.
60. Wada H, Takai Y, Nemoto K, Yamada S,. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004; 58: 1114-1120.
61. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006; 45: 838-847.
62. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010; 210: 744-752, 752-745.
63. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S,. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006; 13: 668-676.
64. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996; 77: 1254-1262.
65. Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP,. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer. 2003; 39: 2150-2164.
66. Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012; 23: 2619-2626.
67. Hoyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012; 82: 1047-1057.
68. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005; 97: 798-804.
69. Dennis K, Makhani L, Zeng L, Lam H, Chow E,. Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials. Radiother Oncol. 2013; 106: 5-14.
70. Gerszten PC, Mendel E, Yamada Y,. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976). 2009; 34 (22 suppl): S78-S92.
71. Sundaresan N, Scher H, DiGiacinto GV, Yagoda A, Whitmore W, Choi IS,. Surgical treatment of spinal cord compression in kidney cancer. J Clin Oncol. 1986; 4: 1851-1856.
72. Wu QJ, Wang Z, Kirkpatrick JP, et al. Impact of collimator leaf width and treatment technique on stereotactic radiosurgery and radiotherapy plans for intra- and extracranial lesions. Radiat Oncol. 2009; 4: 3.
73. Garg AK, Wang XS, Shiu AS, et al. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer. 2011; 117: 3509-3516.
74. Gerszten PC, Burton SA, Ozhasoglu C, et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg Spine. 2005; 3: 288-295.
75. Milker-Zabel S, Zabel A, Thilmann C, Schlegel W, Wannenmacher M, Debus J,. Clinical results of retreatment of vertebral bone metastases by stereotactic conformal radiotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 55: 162-167.
76. Chao ST, Koyfman SA, Woody N, et al. Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys. 2012; 82: 1738-1743.
77. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE,. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010; 76: S42-S49.
78. Ryu S, Jin JY, Jin R, et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer. 2007; 109: 628-636.
79. Sahgal A, Ma L, Gibbs I, et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 77: 548-553.
80. Kirkpatrick JP, Meyer JJ, Marks LB,. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008; 18: 240-243.
81. Rose PS, Laufer I, Boland PJ, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol. 2009; 27: 5075-5079.
82. Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer. 2005; 104: 2244-2254.
83. Ryu S, Rock J, Jain R, et al. Radiosurgical decompression of metastatic epidural compression. Cancer. 2010; 116: 2250-2257.
84. Ryu S, Rock J, Rosenblum M, Kim JH,. Patterns of failure after single-dose radiosurgery for spinal metastasis. J Neurosurg. 2004; 101 (suppl 3): 402-405.
85. Moulding HD, Elder JB, Lis E, et al. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine. 2010; 13: 87-93.
86. Rock JP, Ryu S, Shukairy MS, et al. Postoperative radiosurgery for malignant spinal tumors. Neurosurgery. 2006; 58: 891-898.
87. Hellman S, Weichselbaum RR,. Oligometastases. J Clin Oncol. 1995; 13: 8-10.
88. Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7: e50141.
89. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997; 15: 938-946.
90. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
91. Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007; 205: 231-238.
92. Shah SA, Haddad R, Al-Sukhni W, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006; 202: 468-475.
93. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999; 229: 602-610.
94. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996; 77: 675-682.
95. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008; 26: 1142-1147.
96. Wronski M, Arbit E, Burt M, Perino G, Galicich JH, Brennan MF,. Resection of brain metastases from sarcoma. Ann Surg Oncol. 1995; 2: 392-399.
97. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 1994; 57: 339-344.
98. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363: 1665-1672.
99. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 366: 643-648.
100. Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998; 82: 1062-1070.
101. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27: 1579-1584.
102. Kao J, Chen CT, Tong CC, et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol. 2013; doi: 10.1007/s11523-013-0280-y.
103. Torok J, Wegner RE, Burton SA, Heron DE,. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011; 7: 145-151.
104. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012; 13: 395-402.
105. Torok J, Wegner RE, Burton SA, Heron DE,. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2011; 7: 145-151.
106. Milano MT, Katz AW, Zhang H, Okunieff P,. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012; 83: 878-886.
107. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012; 118: 2962-2970.
108. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012; 13: 395-402.
109. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011; 117: 4060-4069.
110. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology. 2009; 76: 212-219.
111. Cheruvu P, Metcalfe SK, Metcalfe J, Chen Y, Okunieff P, Milano MT,. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol. 2011; 6: 80.
112. De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012; 7: 1547-1555.
113. Hasselle MD, Haraf DJ, Rusthoven KE, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012; 7: 376-381.
114. Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006; 81: 163-167.
115. Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008; 72: 398-403.
116. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P,. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009; 115: 601-608.
117. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M,. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013; 31: 455-460.
118. Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011; 97: 49-55.
119. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012; 82: 940-945.
120. Ranck MC, Golden DW, Corbin KS, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013; 36: 589-595.
121. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011; 6: 34.
122. Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010; 76: 1297-1304.
123. Mishra MV, Showalter TN,. Pushing the limits of radiation therapy for prostate cancer: where do we go next? Semin Oncol. 2013; 40: 297-307.
124. Teh BS, Ishiyama H, Mathews T, et al. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discov Med. 2010; 10: 255-262.
125. Bondiau PY, Courdi A, Bahadoran P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013; 85: 1193-1199.
126. Palta M, Yoo S, Adamson JD, Prosnitz LR, Horton JK,. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 37-42.
127. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011; 79: 965-976.
128. Expert Panel on Radiation Oncology-Bone Metastases;, Lutz ST, Lo SS, Chang EL, et al. ACR Appropriateness Criteria(R) non-spine bone metastases. J Palliat Med. 2012; 15: 521-526.
129. Kirkpatrick JP, Milano MT, Constine LS, Vujaskovic Z, Marks LB,. Late effects and QUANTEC. In:, Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez & Brady's Principles and Practice of Radiation Oncology. 6th edition. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2013: 296-328.
130. Marks LB, Ten Haken RK, Martel MK., Guest editor's introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys. 2010; 76: S1-S2.
131. Formenti SC, Demaria S,. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013; 105: 256-265.
132. Haley ML, Gerszten PC, Heron DE, Chang YF, Atteberry DS, Burton SA,. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine. 2011; 14: 537-542.
133. Shah A, Hahn SM, Stetson RL, Friedberg JS, Pechet TT, Sher DJ,. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013; 119: 3123-3132.
134. Bijlani A, Aguzzi G, Schaal DW, Romanelli P,. Stereotactic radiosurgery and stereotactic body radiation therapy cost-effectiveness results. Front Oncol. 2013; 3: 77.
135. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD,. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract. 2012; 8: e31s-e37s.
136. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 889-897.
137. Teh B, Bloch C, Galli-Guevara M, et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J. 2007; 3: e6.
138. Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiotherapy Oncol. 2005; 77: 88-95.